Silicon Valley tech firm brings encrypted solution for tracking Canadian developer's 15-minute Covid19 rapid antigen test for point of care, and then at-home testing

Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - Afero has entered into a memorandum of understanding (MOU) agreement with Therma Bright Inc. (TSXV: THRM), the "Company" or "Therma Bright"), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies. The mutually beneficial partnership looks to bring Afero's innovation, security and tracking technology to Therma Bright's 15-minute COVID-19 rapid antigen screening solution. Upon completion, the proposed agreement will offer AcuVid™ COVID-19 Rapid Antigen Saliva Tests powered by Afero, with a goal to help communities safely and securely return to work and play using an embedded and encrypted technology for tracking and reporting AcuVID Tests for quality assurance, shipping, logistics, and point-of-care test results. It also paves the way for preparing the AcuVID COVID-19 Rapid Antigen Test for approval for at-home testing. The MOU was competed and signed on April 28, 2021. Both parties expect to complete a definitive agreement and begin work on or before June 1, 2021.

Afero and its innovative solution was introduced to Therma Bright through Ridge Global, who saw an immediate need for serial testing to help slow the pandemic spread while providing accurate, secure reporting on testing results. Backed by the fifth largest IoT patent portfolio globally, the Afero Platform gives partners an agile development process, best-in-class security, and rapid data capture across multiple products and product generations. Afero's mobile application supports advanced quality control features and an intuitive user experience every single time a test is connected. With the secure Afero Cloud, AcuVid™ test status is tracked and managed on a real-time basis for many millions of tests deployed around the world. And with secure Afero Integrations, millions of test results can be shared with government agencies, workplaces, entertainment venues and more.

Even with the proliferation of COVID-19 vaccines across the United States and Canada, the need for secure and reliable rapid antigen testing remains critical to help in slowing the spread of the original COVID19 virus (Wuhan SARS-CoV-2). In addition, Therma Bright has successfully detected its growing list of variants including Brazilian P.1 and P.2 and the UK B.1.1.7 variants. The Afero encrypted QR Code solution will be embedded on each Acuvid Rapid Antigen Test for both enterprise and consumer use. Therma Bright will be able to use this tracking technology for quality assurance and logistics tracking as well as reporting results in a safe, secure manner first for point-of-care facilities, and then for at-home use.

"Our AcuVid COVID-19 Rapid Antigen Test, powered by Afero, will provide users our "Brighter Experience" - a complete end-to-end solution to ensure product tracking, quality control and test validation data are all cryptographically captured and secured to protect individual privacy for every test taken," explained Rob Fia, CEO of Therma Bright. "By integrating Afero's Secure QR Code technology, each AcuVid test deployed will be validated for its efficacy and confirmed on the Afero-powered mobile application. All data captured will be securely stored in the Afero Cloud. If accepted by the end user, their test results can then be transmitted to their personal healthcare practitioner, and/or to their mobile health wallet for ease of use and test verification."

"The opportunity to work with Therma Bright to help mitigate community spread of COVID-19 is a critical step in the growth of our intelligent edge technology," said Joe Britt, Afero co-founder and CEO. "Therma Bright's AcuVid COVID-19 Rapid Antigen Test, powered by Afero, is measurable progress towards enabling everyone on the planet to be able to take a secure, simple, reliable saliva-based test. Afero's expertise in user validation, security, data management and data analytics serve as a critical platform for deploying a "smart" AcuVid solution which reduces risk and adds a layer of quality control which currently doesn't exist with other rapid tests."

To learn more about Afero, please visit www.afero.io.

About Afero

The Afero next-generation Intelligent Edge platform accelerates time to market, provides hardened security from devices to the cloud and from factories to customers, simplifies onboarding to help maximize customer connections, and uses semantic data relationships to streamline machine learning. The Platform is supported by elastic, multi-cloud services that deliver reliability and responsiveness, and a new software engineering model that unifies embedded, mobile, and cloud development.

Afero has assembled world-class mobile, hardware, security, and cloud veterans from Google, Apple, Nest, Danger, Microsoft, Amazon, Logitech, Twitter, and Netflix.

About Ridge Global

Founded by Tom Ridge, the first U.S. Secretary of Homeland Security and 43rd Governor of Pennsylvania, Ridge Global works with C-suite executives and corporate directors to reduce enterprise risk and to build more resilient organizations through innovative preparedness, protection, response and education capabilities.

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the TSXV: THRM, OTCMARKETS:THRBF, FRA:JNX. For more information visit: www.Therma Bright.com and www.coldsores.com

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter

FORWARD LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation, regulatory applications and manufacturing scale up as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82092